Index RUT
P/E -
EPS (ttm) -13.88
Insider Own 4.95%
Shs Outstand 20.95M
Perf Week 120.15%
Market Cap 244.91M
Forward P/E -
EPS next Y -12.91
Insider Trans 102.53%
Shs Float 19.91M
Perf Month 5.05%
Income -245.97M
PEG -
EPS next Q -2.82
Inst Own 54.20%
Short Float 12.99%
Perf Quarter -11.79%
Sales 156.31M
P/S 1.57
EPS this Y 43.81%
Inst Trans -
Short Ratio 3.81
Perf Half Y -24.86%
Book/sh -8.13
P/B -
EPS next Y -66.54%
ROA -67.57%
Short Interest 2.59M
Perf Year -63.01%
Cash/sh 3.63
P/C 3.22
EPS next 5Y -
ROE -
52W Range 4.78 - 42.60
Perf YTD -29.40%
Dividend Est. -
P/FCF -
EPS past 5Y 13.79%
ROI -556.21%
52W High -72.56%
Beta 1.35
Dividend TTM -
Quick Ratio 0.44
Sales past 5Y 98.93%
Gross Margin 89.32%
52W Low 144.82%
ATR (14) 1.46
Dividend Ex-Date -
Current Ratio 0.44
EPS Y/Y TTM 11.50%
Oper. Margin -102.43%
RSI (14) 63.11
Volatility 27.19% 18.39%
Employees 389
Debt/Eq -
Sales Y/Y TTM 59.46%
Profit Margin -157.36%
Recom 1.20
Target Price 88.75
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 51.04%
Payout -
Rel Volume 4.95
Prev Close 8.30
Sales Surprise 78.09%
EPS Surprise -143.56%
Sales Q/Q 195.22%
Earnings May 07 BMO
Avg Volume 678.82K
Price 11.69
SMA20 41.02%
SMA50 5.24%
SMA200 -34.90%
Trades
Volume 3,357,609
Change 40.84%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-06-23 Initiated
Robert W. Baird
Outperform
$8
Jun-06-23 Initiated
Robert W. Baird
Outperform
$60 → $80
Feb-28-23 Resumed
H.C. Wainwright
Buy
$8
Sep-28-22 Initiated
SMBC Nikko
Outperform
$5
Dec-16-21 Initiated
H.C. Wainwright
Buy
$12
Nov-19-19 Resumed
B. Riley FBR
Buy
$6
Apr-22-19 Initiated
B. Riley FBR
Buy
Oct-28-16 Downgrade
H.C. Wainwright
Buy → Neutral
$10 → $5
Oct-27-16 Reiterated
Maxim Group
Buy
Mar-11-16 Upgrade
Maxim Group
Hold → Buy
$7
Dec-16-15 Initiated
Jefferies
Buy
Oct-27-15 Downgrade
Maxim Group
Buy → Hold
Jul-27-15 Reiterated
MLV & Co
Buy
$9 → $11
Jun-11-15 Initiated
Oppenheimer
Outperform
$14
Jan-12-15 Reiterated
Maxim Group
Buy
$10 → $11
Jan-09-15 Reiterated
MLV & Co
Buy
$6 → $9
Jan-09-15 Reiterated
Maxim Group
Buy
$10 → $11
Dec-19-14 Reiterated
Maxim Group
Buy
$8 → $10
May-08-14 Reiterated
Maxim Group
Buy
$17 → $11
Mar-14-14 Reiterated
MLV & Co
Buy
$9 → $11
Show Previous Ratings
Today 08:30AM
Apr-24-24 10:00AM
Apr-23-24 07:30AM
Apr-22-24 04:17AM
Apr-12-24 07:30AM
03:34AM
Loading…
Apr-08-24 03:34AM
Apr-05-24 04:30PM
Apr-03-24 04:19AM
Mar-24-24 04:05PM
Mar-22-24 01:25PM
Mar-15-24 02:11PM
Mar-14-24 01:30PM
08:51AM
07:39AM
(Associated Press Finance)
07:30AM
07:30AM
Loading…
Mar-06-24 07:30AM
Mar-05-24 04:30PM
Feb-29-24 07:30AM
Feb-26-24 07:30AM
Feb-15-24 06:38PM
07:02AM
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Jan-26-24 03:57PM
Jan-22-24 07:30AM
Jan-05-24 04:30PM
Jan-04-24 07:30AM
Dec-24-23 09:45AM
Dec-20-23 07:30AM
Dec-11-23 07:30AM
06:55AM
Loading…
Nov-07-23 06:55AM
06:41AM
(Associated Press Finance)
06:30AM
Oct-26-23 09:05AM
Oct-22-23 12:00PM
Oct-21-23 04:15AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Sep-01-23 04:30PM
Aug-28-23 08:30AM
07:30AM
Aug-24-23 09:54AM
Aug-23-23 02:00PM
(American City Business Journals) -7.28%
01:16PM
(American City Business Journals)
08:00AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents) +11.36%
Aug-17-23 10:04AM
Aug-09-23 08:30AM
Aug-08-23 10:00AM
08:19AM
07:30AM
Aug-03-23 05:25PM
Jul-28-23 07:30AM
Jul-26-23 07:30AM
Jul-20-23 07:30AM
Jul-10-23 07:58AM
(Simply Wall St.) +10.98%
Jun-30-23 11:15AM
Jun-26-23 10:15AM
Jun-06-23 07:46AM
Jun-05-23 09:49AM
07:30AM
May-25-23 07:30AM
May-10-23 06:11AM
May-09-23 07:00PM
09:15AM
08:10AM
08:00AM
May-03-23 09:08AM
Apr-26-23 10:35AM
Apr-25-23 07:30AM
Apr-24-23 07:30AM
Apr-18-23 11:20AM
Apr-17-23 01:55PM
08:47AM
07:30AM
Apr-12-23 04:30PM
Apr-04-23 03:53PM
Mar-30-23 08:41AM
Mar-27-23 03:12PM
09:45AM
Mar-23-23 12:21PM
Mar-17-23 04:31AM
Mar-14-23 04:00PM
08:45AM
07:30AM
Mar-12-23 08:29PM
Mar-11-23 11:24AM
Feb-28-23 07:30AM
07:30AM
Jan-31-23 06:20AM
Jan-26-23 07:30AM
Jan-23-23 02:33PM
07:30AM
Jan-18-23 11:11AM
Jan-10-23 08:30AM
Dec-28-22 10:39AM
Dec-21-22 10:59AM
08:30AM
Dec-19-22 12:55PM
Dec-02-22 04:47PM
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ARMEN GARO H See Remarks Feb 15 '24 Buy 0.65 500,000 324,050 625,969 Feb 15 06:59 PM WIINBERG ULF Director Nov 15 '23 Buy 0.76 25,000 19,000 124,063 Nov 17 04:22 PM AGENUS INC 10% Owner Oct 16 '23 Buy 1.10 429 472 21,772,863 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 13 '23 Buy 1.10 19,373 21,310 21,772,434 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 12 '23 Buy 1.10 3,173 3,488 21,753,061 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 04 '23 Buy 1.09 15,001 16,380 21,749,888 Oct 06 04:26 PM AGENUS INC 10% Owner Aug 29 '23 Buy 1.52 29,678 45,016 21,734,887 Aug 31 05:53 PM AGENUS INC 10% Owner Aug 28 '23 Buy 1.45 12,808 18,570 21,705,209 Aug 28 05:15 PM AGENUS INC 10% Owner Aug 24 '23 Buy 1.54 170,244 262,908 21,692,401 Aug 28 05:15 PM AGENUS INC 10% Owner May 11 '23 Buy 1.43 23,361 33,348 21,640,473 May 12 05:18 PM AGENUS INC 10% Owner May 10 '23 Buy 1.51 22,065 33,296 21,617,112 May 12 05:18 PM AGENUS INC 10% Owner May 05 '23 Buy 0.95 100,200 95,100 21,595,047 May 05 06:00 PM AGENUS INC 10% Owner May 04 '23 Buy 1.22 21,473 26,246 21,494,847 May 05 06:00 PM AGENUS INC 10% Owner May 03 '23 Buy 1.08 128,689 138,843 21,473,374 May 05 06:00 PM
Index -
P/E -
EPS (ttm) -0.65
Insider Own 71.34%
Shs Outstand 34.60M
Perf Week 5.84%
Market Cap 32.18M
Forward P/E -
EPS next Y -0.60
Insider Trans 0.00%
Shs Float 9.95M
Perf Month 1.92%
Income -22.46M
PEG -
EPS next Q -0.15
Inst Own 2.86%
Short Float 0.49%
Perf Quarter 9.97%
Sales 0.00M
P/S -
EPS this Y 13.39%
Inst Trans 32.08%
Short Ratio 0.49
Perf Half Y 4.01%
Book/sh -0.52
P/B -
EPS next Y -6.33%
ROA -172.60%
Short Interest 0.05M
Perf Year -54.76%
Cash/sh 0.10
P/C 9.55
EPS next 5Y -
ROE -1238.95%
52W Range 0.75 - 3.34
Perf YTD -13.32%
Dividend Est. -
P/FCF -
EPS past 5Y 2.37%
ROI -
52W High -72.23%
Beta 0.11
Dividend TTM -
Quick Ratio 0.32
Sales past 5Y -25.00%
Gross Margin -
52W Low 23.67%
ATR (14) 0.10
Dividend Ex-Date -
Current Ratio 0.32
EPS Y/Y TTM 21.35%
Oper. Margin 0.00%
RSI (14) 48.25
Volatility 6.44% 12.95%
Employees 31
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 1.33
Target Price 8.50
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 31.24%
Payout -
Rel Volume 0.33
Prev Close 0.87
Sales Surprise -
EPS Surprise -4.92%
Sales Q/Q -
Earnings Mar 21 BMO
Avg Volume 97.94K
Price 0.93
SMA20 -7.23%
SMA50 -2.89%
SMA200 -20.03%
Trades
Volume 32,317
Change 6.46%
Apr-08-24 12:00PM
Mar-25-24 12:00PM
Mar-22-24 01:25PM
Mar-21-24 11:06PM
(Thomson Reuters StreetEvents)
11:53AM
07:00AM
Loading…
07:00AM
Mar-07-24 07:30AM
Mar-06-24 08:30AM
Feb-14-24 08:00AM
Feb-06-24 08:00AM
Jan-30-24 08:00AM
Dec-20-23 07:30AM
Nov-09-23 08:05AM
07:00AM
Nov-03-23 12:00PM
08:00AM
Loading…
Oct-30-23 08:00AM
Sep-27-23 09:05AM
Aug-24-23 08:30AM
Aug-10-23 07:30AM
Jul-28-23 08:30AM
Jun-05-23 07:30AM
May-22-23 08:30AM
May-18-23 08:30AM
May-11-23 08:00AM
Apr-27-23 08:30AM
Apr-18-23 01:32PM
Apr-16-23 08:03AM
Apr-04-23 09:55AM
Mar-30-23 08:41AM
Mar-29-23 12:00PM
07:36AM
Loading…
Mar-24-23 07:36AM
Mar-21-23 08:00AM
Mar-15-23 08:45AM
Mar-07-23 09:00AM
Feb-16-23 09:28AM
Jan-11-23 02:25PM
Dec-22-22 10:49AM
Nov-17-22 09:00AM
Nov-10-22 09:05AM
Nov-06-22 09:39AM
Nov-03-22 08:00AM
Oct-20-22 09:00AM
Oct-05-22 09:16AM
08:30AM
Aug-31-22 09:00AM
Aug-16-22 06:16AM
Aug-09-22 08:00AM
Aug-02-22 08:30AM
Jul-27-22 08:30AM
May-25-22 08:30AM
May-10-22 08:00AM
May-09-22 08:43AM
Apr-27-22 05:19PM
Mar-18-22 08:30AM
Mar-03-22 04:35PM
09:28AM
Mar-01-22 08:00AM
Jan-15-22 07:47AM
Jan-12-22 09:41AM
Nov-17-21 04:15PM
Nov-12-21 07:30PM
07:00AM
Nov-09-21 08:00AM
08:00AM
Oct-19-21 04:25PM
Oct-15-21 05:31PM
Oct-14-21 08:29PM
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AGENUS INC 10% Owner Oct 16 '23 Buy 1.10 429 472 21,772,863 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 13 '23 Buy 1.10 19,373 21,310 21,772,434 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 12 '23 Buy 1.10 3,173 3,488 21,753,061 Oct 16 05:49 PM AGENUS INC 10% Owner Oct 04 '23 Buy 1.09 15,001 16,380 21,749,888 Oct 06 04:26 PM AGENUS INC 10% Owner Aug 29 '23 Buy 1.52 29,678 45,016 21,734,887 Aug 31 05:53 PM AGENUS INC 10% Owner Aug 28 '23 Buy 1.45 12,808 18,570 21,705,209 Aug 28 05:15 PM AGENUS INC 10% Owner Aug 24 '23 Buy 1.54 170,244 262,908 21,692,401 Aug 28 05:15 PM AGENUS INC 10% Owner May 11 '23 Buy 1.43 23,361 33,348 21,640,473 May 12 05:18 PM AGENUS INC 10% Owner May 10 '23 Buy 1.51 22,065 33,296 21,617,112 May 12 05:18 PM AGENUS INC 10% Owner May 05 '23 Buy 0.95 100,200 95,100 21,595,047 May 05 06:00 PM ARMEN GARO H Director May 05 '23 Sale 0.95 100,000 94,850 1,866,400 May 05 06:27 PM AGENUS INC 10% Owner May 04 '23 Buy 1.22 21,473 26,246 21,494,847 May 05 06:00 PM AGENUS INC 10% Owner May 03 '23 Buy 1.08 128,689 138,843 21,473,374 May 05 06:00 PM ARMEN GARO H Director May 02 '23 Buy 0.95 100,000 94,850 1,978,010 May 04 07:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite